Efficacy Study on Symptomatic Control of Patient With Knee Osteoarthritis Between 0.0125% of Capsaicin to Placebo (OAknee)

This study has been completed.
Sponsor:
Collaborator:
Bangkok Laboratories and Cosmetics
Information provided by:
Khon Kaen University
ClinicalTrials.gov Identifier:
NCT00471055
First received: May 8, 2007
Last updated: July 8, 2008
Last verified: April 2008
  Purpose

The purpose of this study is to determine whether capsaicin gel is effective in treating mild to moderate degrees of osteoarthritis of the knee in the elderly patient compared with placebo gel.


Condition Intervention Phase
Osteoarthritis, Knee Joint
Capsicum
Drug: 0.0125% Capsaicin gel "CAPSIKA gel"
Drug: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Efficacy Study on Symptomatic Control of Patient With Knee Osteoarthritis Between 0.0125% of Capsaicin to Placebo

Resource links provided by NLM:


Further study details as provided by Khon Kaen University:

Primary Outcome Measures:
  • VAS and WOMAC [ Time Frame: 8 months ]
  • VAS and WOMAC [ Time Frame: 8-month study ]

Enrollment: 100
Study Start Date: June 2007
Study Completion Date: December 2007
Primary Completion Date: October 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: A
Capsaicin and placebo controlled,Cross-over design study
Drug: 0.0125% Capsaicin gel "CAPSIKA gel"
Placebo Comparator: B
Capsaicin and placebo controlled,Cross-over design study
Drug: Placebo
Placebo

Detailed Description:

Osteoarthritis (OA) is the most common form of arthritis in the population. It is characterized pathologically by both focal loss of articular cartilage and marginal and central new bone formation. OA of knee, the principal large joint to be affected, results in disabling knee symptoms in an estimated 10% of people older than 55 years, a quarter of whom are severely disabled. The risk of disability attributable to knee OA alone is as great as that due to cardiac disease and greater than that due to any other medical disorder in the elderly. A recent World Health Organization report on the global burden of disease indicates that knee OA is likely to become the fourth most important global cause of disability in women and the eighth most important in men. Knee OA is associated with symptoms of pain and functional disability. Physical disability arising from pain and loss of functional capacity reduces quality of life and increases the risk of further morbidity and mortality. Current treatments aim at alleviating these symptoms of mild to moderate OA by several different methods: non-pharmacological treatment (for example education, exercise, lifestyle changes) or pharmacological treatments(for example paracetamol, NSAIDs and Capsaicin gel topical treatments). Current evidence to support the various treatments in current use, however, is very variable. Capsaicin, the active principle of hot chili pepper, is thought to selectively stimulate unmyelinated C fibre afferent neurons and cause the release of substance P. Prolonged application of capsaicin reversibly depletes stores of substance P, and possibly other neurotransmitters, from sensory nerve endings. This reduces or abolishes the transmission of painful stimuli from the peripheral nerve fibres to the higher centres.There were many study on Capsaicin gel to confirm the effectiveness of capsaicin gel in many dosages. However, there has been no efficacy study on the capsaicin 0.0125% of the Thai produce "Capsika gel " before, therefore, this study is proposed.

  Eligibility

Ages Eligible for Study:   40 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

Subjects eligible for enrollment in the study must meet all of the following criteria:

  1. Subjects who are capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
  2. Ambulatory nom pregnant females and males 40-<80 years of age.
  3. Subjects who withdraw pain medication or nutritional supplements for symptom relief for knee OA for a total of at least 15 days before screening visit 0.
  4. Pain at or below 80 mm on a 100 mm VAS in the index knee.
  5. A documented diagnosis of OA of the knee, or meeting American College of Rheumatology (ACR) clinical criteria for classification of idiopathic (primary) OA for at least 6 months prior to screening. If OA is presented in both knees the investigator will identify which knee will be X-rayed for study entry, with preference for the knee with more severe pain (<80mm VAS).
  6. Has documented radiographic evidence of OA of the knee from the screening Visit radiograph of grade 2 or 3 according to Kellgren and Lawrence Radiographic Grading.
  7. Subjects with baseline minimum joint space width in the medial compartment of the index knee of > 1.5 mm at Baseline, measured from radiographs using the MTP view.
  8. Subjects with baseline minimum joint space width in the lateral compartment of the index knee of > 2.5 mm at Baseline, measured from radiographs using the MTP view.
  9. Subject is able to understand and complete pain/function, global arthritis evaluation, and health outcome assessment.

Exclusion Criteria:

Subjects with any of the following criteria must not be enrolled in the study:

  1. Subjects with history of hypersensitivity to capsaicin.
  2. Subjects with skin lesion at the index knee.
  3. A history of lower extremity surgery within 6 months prior to screening V0.
  4. Significant prior injury to the index knee within 12 months prior to screening V0.
  5. Disease of the spine or other lower extremity joints of sufficient degree to affect the index knee.
  6. Treatment with other drugs potentially affecting bone or cartilage metabolism as described below:

    • chronic systematic corticosteroids
    • hyaluronan injection into the index knee with in the previous 6 months.
    • Diacerin treatment within the last 12 months.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00471055

Locations
Thailand
Weerachai Kosuwon
Khon kaen University, Khon Kaen, Thailand, 40002
Sponsors and Collaborators
Khon Kaen University
Bangkok Laboratories and Cosmetics
Investigators
Principal Investigator: weerachai Kosuwon, M.D Department of Orthopedics, Faculty of Medicine, Khon kaen University
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00471055     History of Changes
Other Study ID Numbers: Khonkaen-ortho 1
Study First Received: May 8, 2007
Last Updated: July 8, 2008
Health Authority: Thailand: Khon Kaen University Ethics Committee for Human Research

Keywords provided by Khon Kaen University:
osteoarthritis
knee
capsaicin gel
capsicum

Additional relevant MeSH terms:
Osteoarthritis
Osteoarthritis, Knee
Arthritis
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Capsaicin
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Antipruritics
Dermatologic Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on July 29, 2014